@john.ditlof's testosterone therapy claims need context

What does this video actually claim?

@john.ditlof presents testosterone replacement therapy as a solution for men with low testosterone symptoms. He emphasizes that TRT can improve energy, mood, and sexual function in men who have clinically low testosterone levels.

The video suggests that many men suffer unnecessarily from hypogonadism without realizing testosterone therapy could help. Ditlof positions TRT as an underutilized treatment option that could benefit more men than currently receive it.

Does the science support testosterone therapy?

Yes, but with important caveats. The Testosterone Trials (Snyder et al., NEJM, 2016) showed modest improvements in sexual function and mood in men over 65 with testosterone levels below 275 ng/dL.

However, the benefits weren't dramatic. Sexual activity increased by 1.5 episodes per month compared to placebo. Mood improvements were small and didn't reach statistical significance in the largest trial. The TRAVERSE study (Lincoff et al., NEJM, 2023) followed 5,246 men for 33 months and found no increased cardiovascular risk, addressing a major safety concern.

But here's what Ditlof doesn't mention: about 40% of men in these trials didn't respond meaningfully to treatment.

What are the real risks he's not discussing?

TRT isn't the simple solution this video implies. The therapy can reduce sperm production by 90% within 10 weeks, according to studies by Liu et al. Treatment often requires lifelong commitment since stopping can leave men with lower testosterone than before they started.

Blood clot risk increases, particularly in the first year. A 2014 study by Sharma et al. found a 63% higher risk of blood clots in the first six months of treatment. Regular monitoring for prostate issues, sleep apnea worsening, and elevated red blood cell counts is essential.

The FDA has required warnings about cardiovascular and blood clot risks since 2015 for good reason.

Who actually benefits from testosterone therapy?

Men with consistently low testosterone (typically below 300 ng/dL on two separate morning tests) and clear symptoms see the best results. The Endocrine Society guidelines recommend confirming both biochemical deficiency and clinical symptoms before starting treatment.

Age matters too. Younger men with secondary hypogonadism might recover natural production with alternative treatments. The TRAVERSE study focused on men with cardiovascular risk factors, so we have less long-term safety data for healthy younger men.

What Ditlof gets right is that many men with legitimate hypogonadism go undiagnosed. But the solution isn't assuming TRT works for everyone with fatigue or low libido.

What should you actually know about TRT?

Testosterone therapy works for the right candidates, but it's not a fountain of youth. Realistic expectations matter: energy might improve moderately, but don't expect dramatic life changes.

Generic testosterone cypionate costs about $30-50 monthly, while compounded formulations can run $200-400. Insurance coverage varies widely. Starting doses typically range from 100-200mg weekly, adjusted based on blood levels and response.

The key is proper evaluation first. That means comprehensive blood work, not just total testosterone, and ruling out other causes of symptoms like sleep disorders or depression.